Advanced Diagnosis and Treatment Strategies for Bladder Cancer

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 6066

Special Issue Editors


E-Mail Website
Guest Editor
Urology Department, Medical University of Vienna, Vienna, Austria
Interests: uro-oncology; cancer biology; treatment response; biomarkers and cancer
Special Issues, Collections and Topics in MDPI journals
Department of Urology, University Hospital CHUV, Lausanne, Switzerland
Interests: bladder cancer; endourology; circulating tumor cells; urologic oncology; urolithiasis; surgical oncology; minimally invasive surgery; cystoscopy; kidney stones; bladder

Special Issue Information

Dear Colleagues,

This Special Issue aims to bring together new research and perspectives regarding the diagnosis, treatment and management of patients with bladder cancer. This Special Issue of Diagnostics will include a broad spectrum of research related to bladder cancer from basic research to up-to-date clinical insights.

The issue will be subdivided into two parts: non-muscle-invasive bladder cancer and muscle-invasive bladder cancer.

Dr. Mihai Dorin Vartolomei
Dr. Beat Roth
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • artificial intelligence
  • chemo-hyperthermia
  • BCG shortage
  • BCG unresponsive
  • intravesical therapies
  • multimodaltherapie
  • surgical treatment
  • immunotherapy
  • target therapy
  • oncological outcomes
  • functional outcomes
  • quality of life
  • psychological distress
  • body image

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 829 KiB  
Article
Impact of Enhanced Recovery after Surgery® Protocol Compliance on Length of Stay, Bowel Recovery and Complications after Radical Cystectomy
by Nuno Grilo, François Crettenand, Perrine Bohner, Sonia Cristina Rodrigues Dias, Yannick Cerantola and Ilaria Lucca
Diagnostics 2024, 14(3), 264; https://doi.org/10.3390/diagnostics14030264 - 25 Jan 2024
Viewed by 807
Abstract
Background: Despite existing standardized surgical techniques and the development of new perioperative care protocols, radical cystectomy (RC) morbidity remains a serious challenge for urologists. Postoperative ileus (POI) is one of the most common postoperative complications, often leading to a longer length of stay [...] Read more.
Background: Despite existing standardized surgical techniques and the development of new perioperative care protocols, radical cystectomy (RC) morbidity remains a serious challenge for urologists. Postoperative ileus (POI) is one of the most common postoperative complications, often leading to a longer length of stay (LOS). The aim of our study was to assess the impact of compliance to the Enhanced Recovery After Surgery (ERAS®) protocol on bowel recovery, 30-day complications and LOS after RC for bladder cancer (BC). Methods: Data from consecutive patients undergoing RC for BC within an ERAS® dedicated protocol were analyzed. Exclusion criteria were urinary diversion other than ileal conduit and palliative RC. Patients were divided into two groups according to their compliance (A: low-compliance and B: high-compliance). ERAS® compliance was extracted from the ERAS® Interactive Audit System (EIAS) database. Postoperative complications were prospectively recorded by a dedicated study nurse 30 days after RC. POI was defined as the placement of a nasogastric tube. Logistic regression analysis was used to identify predictors of 30-day complications and POI. Results: After considering the exclusion criteria, 108 patients were included for the final analysis. The median global compliance to the ERAS® protocol was 61%. A total of 78 (72%) patients had a compliance <65% (group A), while the remaining 30 (28%) had a compliance >65% (group B). No significant differences were found among the two groups regarding the 30-day complication rate (86% in group A versus 73% in group B, p = 0.82) and LOS (14 days in group A versus 15 days in group B, p = 0.82). The time to stool was significantly shorter in group B (4 days versus 6 days, p = 0.02), and the time to tolerate solid food was slightly faster in group B but not significant (8 versus 7 days, p = 0.23). The POI rate was significantly lower in patients with a higher ERAS® compliance (20% versus 46%, p = 0.01). A multivariate analysis showed that ERAS® compliance was not significantly associated with 30-day total complications. However, a lower compliance to the ERAS® protocol and age > 75 years were significant independent predictors of POI. Conclusions: Our study provides further evidence to support the beneficial effect of the ERAS® protocol in patients undergoing RC, particularly in terms of facilitating a faster recovery of bowel function and preventing POI. Future research should focus on investigating novel approaches and interventions to improve compliance with the ERAS® protocol. This may involve patient education, multidisciplinary teamwork, and continuous quality improvement initiatives. Full article
(This article belongs to the Special Issue Advanced Diagnosis and Treatment Strategies for Bladder Cancer)
Show Figures

Figure 1

17 pages, 12011 KiB  
Article
Differential Protein Expression Patterns of HOXA13 and HOXB13 Are Associated with Bladder Cancer Progression
by Fee-Wai Chin, Huzlinda Hussin, De-Ming Chau, Teng-Aik Ong, Rosna Yunus, Azad Hassan Abdul Razack, Khatijah Yusoff, Soon-Choy Chan and Abhi Veerakumarasivam
Diagnostics 2023, 13(16), 2636; https://doi.org/10.3390/diagnostics13162636 - 9 Aug 2023
Cited by 1 | Viewed by 1036
Abstract
Bladder cancer is a common urological cancer and has the highest recurrence rate of any cancer. The aim of our study was to profile and characterize the protein expression of homeobox A13 (HOXA13) and homeobox B13 (HOXB13) genes in [...] Read more.
Bladder cancer is a common urological cancer and has the highest recurrence rate of any cancer. The aim of our study was to profile and characterize the protein expression of homeobox A13 (HOXA13) and homeobox B13 (HOXB13) genes in Malaysian bladder cancer patients. The protein expression of HOXA13 and HOXB13 in formalin-fixed paraffin-embedded (FFPE) bladder cancer tissues was determined by immunohistochemistry (IHC) analysis. The association between HOXA13/HOXB13 protein expression and demographic/clinicopathological characteristics of the bladder cancer patients was determined by chi-square analysis. Approximately 63.6% of the bladder cancer tissues harbored high HOXA13 expression. High HOXA13 expression was significantly associated with non-muscle invasive bladder cancer, lower tumor grade, higher number of lymph node metastases, and recurrence risk. In contrast, low HOXB13 expression (including those with negative expression) was observed in 71.6% of the bladder cancer tissues analyzed. Low HOXB13 expression was significantly associated with muscle-invasive bladder cancer, higher tumor stage, tumor grade, and metastatic risk. Both HOXA13 and HOXB13 protein expression were found to be associated with bladder tumorigenesis. The putative oncogenic and tumor suppressive roles of HOXA13 and HOXB13, respectively, suggest their potential utility as biomarkers in bladder cancer. Full article
(This article belongs to the Special Issue Advanced Diagnosis and Treatment Strategies for Bladder Cancer)
Show Figures

Figure 1

Review

Jump to: Research

34 pages, 1228 KiB  
Review
Homeobox Gene Expression Dysregulation as Potential Diagnostic and Prognostic Biomarkers in Bladder Cancer
by Fee-Wai Chin, Soon-Choy Chan and Abhi Veerakumarasivam
Diagnostics 2023, 13(16), 2641; https://doi.org/10.3390/diagnostics13162641 - 10 Aug 2023
Viewed by 1128
Abstract
Homeobox genes serve as master regulatory transcription factors that regulate gene expression during embryogenesis. A homeobox gene may have either tumor-promoting or tumor-suppressive properties depending on the specific organ or cell lineage where it is expressed. The dysregulation of homeobox genes has been [...] Read more.
Homeobox genes serve as master regulatory transcription factors that regulate gene expression during embryogenesis. A homeobox gene may have either tumor-promoting or tumor-suppressive properties depending on the specific organ or cell lineage where it is expressed. The dysregulation of homeobox genes has been reported in various human cancers, including bladder cancer. The dysregulated expression of homeobox genes has been associated with bladder cancer clinical outcomes. Although bladder cancer has high risk of tumor recurrence and progression, it is highly challenging for clinicians to accurately predict the risk of tumor recurrence and progression at the initial point of diagnosis. Cystoscopy is the routine surveillance method used to detect tumor recurrence. However, the procedure causes significant discomfort and pain that results in poor surveillance follow-up amongst patients. Therefore, the development of reliable non-invasive biomarkers for the early detection and monitoring of bladder cancer is crucial. This review provides a comprehensive overview of the diagnostic and prognostic potential of homeobox gene expression dysregulation in bladder cancer. Full article
(This article belongs to the Special Issue Advanced Diagnosis and Treatment Strategies for Bladder Cancer)
Show Figures

Figure 1

22 pages, 2521 KiB  
Review
Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement
by Matteo Ferro, Ugo Giovanni Falagario, Biagio Barone, Martina Maggi, Felice Crocetto, Gian Maria Busetto, Francesco del Giudice, Daniela Terracciano, Giuseppe Lucarelli, Francesco Lasorsa, Michele Catellani, Antonio Brescia, Francesco Alessandro Mistretta, Stefano Luzzago, Mattia Luca Piccinelli, Mihai Dorin Vartolomei, Barbara Alicja Jereczek-Fossa, Gennaro Musi, Emanuele Montanari, Ottavio de Cobelli and Octavian Sabin Tataruadd Show full author list remove Hide full author list
Diagnostics 2023, 13(13), 2308; https://doi.org/10.3390/diagnostics13132308 - 7 Jul 2023
Cited by 11 | Viewed by 1966
Abstract
Artificial intelligence is highly regarded as the most promising future technology that will have a great impact on healthcare across all specialties. Its subsets, machine learning, deep learning, and artificial neural networks, are able to automatically learn from massive amounts of data and [...] Read more.
Artificial intelligence is highly regarded as the most promising future technology that will have a great impact on healthcare across all specialties. Its subsets, machine learning, deep learning, and artificial neural networks, are able to automatically learn from massive amounts of data and can improve the prediction algorithms to enhance their performance. This area is still under development, but the latest evidence shows great potential in the diagnosis, prognosis, and treatment of urological diseases, including bladder cancer, which are currently using old prediction tools and historical nomograms. This review focuses on highly significant and comprehensive literature evidence of artificial intelligence in the management of bladder cancer and investigates the near introduction in clinical practice. Full article
(This article belongs to the Special Issue Advanced Diagnosis and Treatment Strategies for Bladder Cancer)
Show Figures

Figure 1

Back to TopTop